This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Canaccord Genuity analyst Joseph Vafi downgraded the rating for ASGN Incorporated ASGN from Buy to Hold and lowered the price target from $115 to $55. ASGN shares closed at $51.76 on Thursday. See how other analysts view this stock.
  • JP Morgan analyst Alexei Gogolev downgraded SS&C Technologies Holdings, Inc. SSNC from Overweight to Neutral and lowered the price target from $90 to $86. SS&C Technologies shares closed at $77.43 on Thursday. See how other analysts view this stock.
  • Macquarie analyst Linda Huang downgraded the rating for TAL Education Group TAL from Outperform to Neutral and cut the price target from $14.5 to $10.9. TAL Education shares closed at $8.93 on Thursday. See how other analysts view this stock.
  • Wells Fargo analyst Tiago Fauth downgraded United Therapeutics Corporation UTHR from Overweight to Equal-Weight and slashed the price target from $395 to $314. United Therapeutics shares closed at $296.42 on Thursday. See how other analysts view this stock.

Considering buying UTHR stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock

ASGNASGN Inc
$51.37-0.75%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
10.28
Growth
19.55
Quality
72.69
Value
41.26
Price Trend
Short
Medium
Long
Got Questions? Ask
Which healthcare stocks may benefit from UTHR's downgrade?
How will ASGN Incorporated's downgrade impact tech investments?
Is there a buying opportunity in SS&C Technologies after its downgrade?
What does TAL's rating change mean for education tech stocks?
How might United Therapeutics's price target affect biotech investors?
Are analysts too cautious on Philip Morris post-upgrade?
Which pharmaceutical companies could be undervalued after UTHR's downgrade?
Could healthcare ETFs be a safer bet after these downgrades?
What sectors might be affected by analyst downgrades in general?
Which investment strategies could capitalize on these rating changes?
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Comments
Loading...